Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer. - Phillips, R.; Proudfoot, J.; Davicioni, E.; Spratt, D.E.; Feng, F.Y.; Simko, J.; Den, R.B.; Pollack, A.; Rosenthal, S.A.; Sartor, O.; Sweeney, C.; Attard, G.; et al. (International Journal of Radiation Oncology, Biology, Physics, 2023)